We analyzed the expression level of USP39 in the cohort of human NAFLD patients and found USP39 to be significantly downregulated in high NAFLD activity score group compared with low NAFLD activity score group (Fig. 1e). The gene discussed is USP39; the disease is metabolic dysfunction-associated steatotic liver disease.